A novel monoclonal antibody against Notch1 targets leukemia-associated mutant Notch1 and depletes therapy resistant cancer stem cells in solid tumors

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Sharma, Ankur ^a   Gadkari, Rupali A ^a   Ramakanth, Satthenapalli V ^a   Padmanabhan, Krishnanand ^a   Madhumathi, Davanam S ^b   Devi, Lakshmi ^b   Appaji, Lingappa ^b   Aster, Jon C ^c   Rangarajan, Annapoorni ^a   Dighe, Rajan R ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 604.107; NOTCH1 PROTEIN, HUMAN; NOTCH1 RECEPTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY AFFINITY; CANCER STEM CELL; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HEK293 CELLS; HUMANS; MICE, NUDE; MUTATION; NEOPLASTIC STEM CELLS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTOR, NOTCH1; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930933316     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11012     Document Type: Article

References (47)

1. Guruharsha, K., Kankel, M. W. & Artavanis-Tsakonas, S. The Notch signalling system: recent insights into the complexity of a conserved pathway. Nature Reviews Genetics 13, 654-666 (2012).
2. Kopan, R., Ilagan, M. & Xenia, G. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137, 216-233 (2009).
3. Jarriault, S. et al. Signalling downstream of activated mammalian Notch. Nature 377, 355-358 (1995).
4. Louvi, A. & Artavanis-Tsakonas, S. Notch and disease: A growing field. Seminars in Cell & Developmental Biology 23, 473-480, (2012).
5. Allenspach, E., Maillard, I., Aster, J. & Pear, W. Notch signaling in cancer. Cancer biology & therapy 1, 466-476 (2002).
6. Radtke, F. & Raj, K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nature Reviews Cancer 3, 756-767 (2003).
7. Korkaya, H. & Wicha, M. S. HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clinical Cancer Research 15, 1845 (2009).
8. Chen, J. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522-526 (2012).
9. Qiu, M. et al. Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells. Cancer letters 328, 261-270 (2012).
10. McAuliffe, S. M. et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proceedings of the National Academy of Sciences 109, E2939-E2948 (2012).
11. Pannuti, A. et al. Targeting Notch to target cancer stem cells. Clinical Cancer Research 16, 3141-3152 (2010).
12. Van Es, J. H. et al. Notch/-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959-963 (2005).
13. Aster, J. C. & Blacklow, S. C. Targeting the notch pathway: twists and turns on the road to rational therapeutics. Journal of Clinical Oncology 30, 2418-2420 (2012).
14. Krop, I. et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. Journal of Clinical Oncology 30, 2307-2313 (2012).
15. Tolcher, A. W. et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. Journal of Clinical Oncology 30, 2348-2353 (2012).
16. Aste-Amézaga, M. et al. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS One 5, e9094 (2010).
17. Sharma, A., Paranjape, A. N., Rangarajan, A. & Dighe, R. R. A Monoclonal Antibody against Human Notch1 Ligand-Binding Domain Depletes Subpopulation of Putative Breast Cancer Stem-like Cells. Molecular cancer therapeutics 11, 77-86 (2012).
18. Wu, Y. et al. Therapeutic antibody targeting of individual Notch receptors. Nature 464, 1052-1057 (2010).
19. Weng, A. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269 (2004).
20. Gordon, W. et al. Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. Blood 113, 4381 (2009).
21. Ankur, S., Annapoorni, R. & Rajan, R. D. Antibodies against the extracellular domain of human Notch1 receptor reveal the critical role of epidermal-growth-factor-like repeats 25-26in ligand binding and receptor activation. Biochemical Journal 449, 519-530 (2013).
22. Malecki, M. J. et al. Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. Molecular and cellular biology 26, 4642-4651 (2006).
23. Šali, A. & Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. Journal of molecular biology 234, 779-815 (1993).
24. Gordon, W. R. et al. Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. Blood 113, 4381-4390 (2009).
25. DeLano, W. L. The PyMOL molecular graphics system. (2002). Available at: http://www.pymol.org (Accessed: Februry 2013)
26. Rekha, N., Machado, S., Narayanan, C., Krupa, A. & Srinivasan, N. Interaction interfaces of protein domains are not topologically equivalent across families within superfamilies: Implications for metabolic and signaling pathways. Proteins: Structure, Function, and Bioinformatics 58, 339-353 (2005).
27. Majumdar, R., Railkar, R. & Dighe, R. R. Docking and free energy simulations to predict conformational domains involved in hCG-LH receptor interactions using recombinant antibodies. Proteins: Structure, Function, and Bioinformatics 79, 3108-3122 (2011).
28. Dey, D. et al. Phenotypic and functional characterization of human mammary stem/progenitor cells in long term culture. PLoS One 4, DOI: 10.1371/journal.pone.0005329 (2009).
29. Roti, G. et al. Complementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated Cancer. Cancer Cell 23, 390-405 (2013).
30. Ma, W. et al. NOTCH1 Signaling Promotes Human T-Cell Acute Lymphoblastic Leukemia Initiating Cell Regeneration in Supportive Niches. PLoS One 7, e39725 (2012).
31. Koch, U. & Radtke, F. Chapter Thirteen-Notch Signaling in Solid Tumors. Current topics in developmental biology 92, 411-455 (2010).
32. Mittal, S., Subramanyam, D., Dey, D., Kumar, R. & Rangarajan, A. Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis. Molecular Cancer 8, 128 (2009).
33. Dey, D. et al. Phenotypic and functional characterization of human mammary stem/progenitor cells in long term culture. PLoS One 4, e5329 (2009).
34. Dontu, G., Liu, S. & Wicha, M. S. Stem cells in mammary development and carcinogenesis. Stem Cell Reviews and Reports 1, 207-213 (2005).
35. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences 100, 3983-3988 (2003).
36. Hassan, K. A. et al. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clinical Cancer Research 19, 1972-1980 (2013).
37. Saxena, M., Stephens, M. A., Pathak, H. & Rangarajan, A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell death & disease 2, e179 (2011).
38. Cho, S. et al. Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proceedings of the National Academy of Sciences 108, 20778-20783 (2011).
39. Rangarajan, A. Cancer Stem Cells: The Real Enemies within Cancer? Journal of the Indian Institute of Science 92, 313-320 (2012).
40. Pannuti, A. et al. Targeting Notch to target cancer stem cells. Clinical Cancer Research 16, 3141 (2010).
41. Lapouge, G. et al. Skin squamous cell carcinoma propagating cells increase with tumour progression and invasiveness. The EMBO Journal 31, 4563-4575 (2012).
42. Wang, Z. et al. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1806, 258-267 (2010).
43. Singh, A. & Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751 (2010).
44. Rizzo, P. et al. Rational targeting of Notch signaling in cancer. Oncogene 27, 5124-5131 (2008).
45. Dontu, G. et al. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 6, R605-R615 (2004).
46. Ricci-Vitiani, L. et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115 (2006).
47. McGowan, P. M. et al. Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Molecular Cancer Research 9, 834-844 (2011).